Similar articles

• [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].

  Kondo T. Kondo T. Nihon Jinzo Gakkai Shi. 2012;54(5):574-80. Nihon Jinzo Gakkai Shi. 2012. PMID: 22991835 Review. Japanese. No abstract available.
• Editorial comment.

  Rini BI, Shah SN. Rini BI, et al. Urology. 2010 May;75(5):1114-5; author reply 1115. doi: 10.1016/j.urology.2009.07.1291. Urology. 2010. PMID: 20451727 No abstract available.
• Editorial comment.

  Vaishampayan U. Vaishampayan U. Urology. 2010 May;75(5):1114; author reply 1115. doi: 10.1016/j.urology.2009.07.1290. Urology. 2010. PMID: 20451726 No abstract available.
• New therapeutic options for renal cell carcinoma.

  Stadler W. Stadler W. Clin Adv Hematol Oncol. 2006 Jun;4(6):429-30. Clin Adv Hematol Oncol. 2006. PMID: 16981664 No abstract available.
• CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.

  Stein MN, Flaherty KT. Stein MN, et al. Clin Cancer Res. 2007 Jul 1;13(13):3765-70. doi: 10.1158/1078-0432.CCR-06-2844. Clin Cancer Res. 2007. PMID: 17606705 Review. No abstract available.